G. R. Driver — Aramaic documents of the fifth century B. C., transcr. and ed. with translation and notes, with help from a typescript by E. Mittwoch, W. B. Henning H. J. Polotsky and F. Rosenthal. Oxford, Clarendon Press, 1954

Costaz Louis. G. R. Driver — Aramaic documents of the fifth century B. C., transcr. and ed. with translation and notes, with help from a typescript by E. Mittwoch, W. B. Henning H. J. Polotsky and F. Rosenthal. Oxford, Clarendon Press, 1954. In: Mélanges de l'Université Saint-Joseph, tome 31, 1954. pp. 424-426

Rev. Thomas Arayathinal, M.O.L. — Aramaic Grammar (Method Gaspey-Otto-Sauer). St. Joseph’s Press, Mannanam (Kerala State, S. India), 1957

Costaz Louis. Rev. Thomas Arayathinal, M.O.L. — Aramaic Grammar (Method Gaspey-Otto-Sauer). St. Joseph’s Press, Mannanam (Kerala State, S. India), 1957. In: Mélanges de l'Université Saint-Joseph, tome 36, 1959. pp. 248-249

R. Köbert, s. j. — Vocabularium Syriacum. Rome, Pontificium Institutum Biblicum, 1956

Costaz Louis. R. Köbert, s. j. — Vocabularium Syriacum. Rome, Pontificium Institutum Biblicum, 1956. In: Mélanges de l'Université Saint-Joseph, tome 34, 1957. pp. 308-309

Histoire du bataillon des jeunes citoyens à l'attaque du faubourg Antoine, le 4 prairial an III / par Louis Costaz,...

Avec mode text

L'année polaire international au Muséum national d'Histoire naturelle

International audienc

L’année 2021 dans tous ses états : une synthèse digérée

International audience5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to assess surgical resectability at diagnosis or after neoadjuvant chemotherapy. However, there is no clinical or biological marker that can correctly predict resectability and may be able to avoid a second laparoscopic exploration for initially unresectable diseases. Our aim was to assess circulating tumor DNA (ctDNA) value as a predictive non-invasive marker of evolution towards resectability for patients with epithelial ovarian cancer receiving first-line chemotherapy. Methods: We explored in this work one of the secondary objectives of the CIDOC study (NCT03302884). CIDOC is a multicenter prospective study aiming to explore ctDNA value as early marker of disease relapse after first-line treatment for epithelial ovarian cancer. Patients with mucinous histology or early stages not requiring chemotherapy are excluded. Plasma samples are collected at diagnosis, during neoadjuvant chemotherapy, and during follow-up. After DNA extraction, panel-based next generation sequencing is performed on both tumor samples and germline DNA, and somatic mutations of interest are selected for ctDNA monitoring. ctDNA analyses are conducted using droplet digital PCR (BioRad QX200) by measuring the variant allele fraction (VAF) of previously identified mutations. Results: This intermediary analysis has included 47 patients diagnosed between March 2017 and December 2019. Median age was 69 years old (48 – 84). Most of the patients had advanced disease (89.4% stage FIGO III or IV), serous histology (94.8%), and high grade tumor (92.3%). Most of the patients underwent complete interval cytoreductive surgery (76.3% vs 17.4% complete upfront surgery). Most of the tumors had TP53 mutations (85.1%), following by alterations involving DNA repair genes (38.3%). Median cell-free DNA concentration at baseline was 0.38 ng/µL (0 – 12.8). ctDNA was identified in 92.1% of patients at baseline with a median VAF of 1.84% (0 – 42.52%). ctDNA VAF was correlated to the peritoneal dissemination ( p= 0.039) assessed with the peritoneal cancer index. ctDNA clearance after preoperative chemotherapy tended to be correlated to achievement of complete interval surgery for patients receiving neoadjuvant chemotherapy ( p= 0.108). Conclusions: ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy. If confirmed in larger populations, this may enable to avoid additional surgical explorations for patients who remain ctDNA positive after chemotherapy. Clinical trial information: NCT03302884